The adaptive platform trial is sponsored by Quantum Leap Healthcare Collaborative (QLHC) and is intended to quickly assess agents that demonstrate promise for two primary endpoints in these patients.
The time to recovery, described as the decline in oxygen demand, and the morality risk are the two endpoints.
In the narsoplimab arm of the trial, 91 subjects were enrolled across 27 sites in the US.
These subjects were analysed against a control arm with 116 subjects.
According to the findings, narsoplimab lowered the risk of mortality in trial participants.
It was also found to offer the greatest decline in mortality risk so far across all drugs evaluated in the trial.
In the trial, the agent did not reduce the time to recovery in critically ill Covid-19 patients.
No new safety signals linked to narsoplimab in critically ill Covid-19 setting were reported in the trial.
A lead inhibitor of MASP-2, narsoplimab acts on the lectin pathway of complement.
Omeros chairman and CEO Gregory Demopulos said: “We appreciate QLHC’s efforts to accelerate the identification of effective therapeutics against Covid-19 and are pleased that, despite the trial’s challenges inherent in that objective, a survival benefit was reported for narsoplimab.
“Work continues in our laboratories, both in Seattle and at the University of Cambridge, to build on our published findings on the role of the lectin pathway and the MASP-2 inhibitor narsoplimab in severe acute Covid-19, PASC, or long Covid, and other related life-threatening infections, as well as on our set of assays to identify at-risk patients early in these diseases.”
In May last year, the company reported that 80% of the critically ill patients in the second cohort of its Covid-19 study of narsoplimab, recovered, survived, and were discharged in Italy.